Graeme Martin Ph.D.

President and CEO

Dr. Martin is President and CEO of Takeda Research Investment, Inc, with day-to-day responsibility for operations. He brings more than 30 years R&D experience in large Pharma as well as Biotech, and was responsible for three IND submissions one of which led to the launch of Zomig® now marketed worldwide for the acute treatment of migraine. Dr Martin joined TVI in 2003, and has been responsible for building a portfolio of strategic investments representing more than US$45MM under management. He received his Bachelor of Science degree in Pharmacology from the University of Bath, UK and his doctorate from University College, London, UK.